Modern tactics of treating patients with Peyronie’s disease

Authors

  • V.P. Stus Dnipropetrovsk State Medical Academy, Ukraine
  • A.L. Suvarian Dnipropetrovsk regional hospital of І.І. Mechnikov, Ukraine

DOI:

https://doi.org/10.26641/2307-5279.23.3.2019.178773

Keywords:

Peyronies disease, fibrotic plaque, curvature of the penis, corporoplasty

Abstract

Peyronie’s disease (PD) or fibroplastic induction of the penis has a negative effect on the quality of life of patients due to fibrous damage to the protein coat of the cavernous bodies, leading to curvature of the penis, development of erectile dysfunction, depressive symptoms in the patient, and psycho-sexual disorders in sexual couples. In the treatment of PD, conservative and surgical methods are used. Due to the lack of clear understanding of the etiology and pathogenesis of PD, there are no sufficiently effective drugs for conservative therapy. The main treatment for Peyronie’s disease is surgical. From 2006 to 2019, at the Urology Clinic of the Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov treated 114 patients with Peyronie’s disease aged 23 to 78 years (cf. 43.16 ± 28.46). Of these, 47 patients (41.23%) underwent conservative treatment, and 67 patients (58.77%) underwent surgical treatment. Out of 61 patients: 8 patients (13.11%) used plication surgery: Nesbit-Shcheplev operation to 2 patients (3.28%), Essed-Schroder operation to 6 patients (9.84%); 21 patients (34.43%); corporoplasty was performed with preserved erectile function using a section of the wide femoral fascia (ZKPSHFB), and 31 patients (40.98%) had a vaginal membrane of the testicle (ZKVOYA). Endofalloprosthetics were performed in 8 patients (11.94%) with severe erectile dysfunction. After conservative therapy, the pain syndrome was stopped in all patients 47 (100%), stabilization of the curvature was achieved in 43 (91.49%) patients, a decrease in the angle of curvature (up to 15°) in 11 patients (23.40%), and a reduction in the volume of the plaque in 12 patients (25.53%), improved erectile function in 35 patients (92.10%) (IIEF before treatment 18.4 ± 1.5 points, after treatment 23.6 ± 1.2 points). Resorption of the plaque was not observed in anyone. After plication operations, the patient achieved straightening of the penis, without significant loss of penile length. In 1 patient (12.5%), a decrease in the sensitivity of the glans penis was observed, which is within 3 months. fully restored. Subcutaneous hematomas of the penis that do not require additional surgical procedures were noted in 4 patients: (50%). Erectile dysfunction was noted in 1 patient with impaired sensitivity of the head (12.5%), which was corrected by additional conservative therapy. All patients who underwent replacement corporoplasty with a section of the wide fascia of the femur achieved correction of penile deformity without shortening the size of the penis and restoration of copulative function. Only 3 patients (14.3%) retained residual curvature of the penis (less than 10Ъ), which did not interfere with sexual intercourse. In the early postoperative period, 8 patients (13.11%) showed a decrease in the sensitivity of the glans penis, and 5 (19.04%) for 3 months. sensitivity was fully restored, in 2 (3.28%) complaints remained. Subcutaneous hematomas of the penis that do not require additional surgical interventions were noted in 11 patients: (18.03%). Erectile dysfunction was noted by 2 (9.52%) patients, which was corrected by additional conservative therapy. Graft retraction was noted in 2 (9.52%), due to the fact that these patients did not undergo postoperative rehabilitation. In case of cororoplasty with a transplant of the vaginal sheath of the testis (ZKVOY), only 4 patients (12.90%) retained residual curvature of the penis (less than 10Ъ), which did not interfere with sexual intercourse. In the early postoperative period, 9 (29%) showed a decrease in the sensitivity of the glans penis, and 6 (19.35%) for 3 months. sensitivity was fully restored, in 3 (9.67%) complaints remained. Subcutaneous hematomas of the penis that do not require additional surgical interventions were noted in 9 (29%). Erectile dysfunction was noted by 6 patients (19.35%), which was corrected by additional conservative therapy. In 1 (3.22%) patient, due to recurrence of the disease and worsening erection, endofalloprosthetics were performed in a year. In 1 patient (3.22%), deformation of the foreskin was noted. After 2 months, circumcisio was given to this patient. Graft retraction was noted in 5 (16.1%). However, in these patients, the residual curvature was less than 30 °, which did not interfere with sexual activity. Findings. Thus, the effectiveness of conservative therapy remains low. But it is necessary in order to stabilize the inflammatory process, relieve pain, improve and maintain erectile function. Surgical treatment is a highly effective method and leads in 100% of cases to the restoration of the patient’s copulative function.

References

Rosen R., Catania J., Lue T. et al. Impact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008. No 5. P.1977–1984.

Schwarzer U., Sommer F., Klotz T., Braun M. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001. No 88. P. 727–730.

Dibenedetti D.B., Nguyen D., Zografos L. et al. A Population-Based Study of Peyronie’s Disease: Prevalence and Treatment Patterns in the United States. Adv. Urol. 2011.

Гурженко Ю.Н. Фибропластическая индурация полового члена. К., 2004. 382 с.

Щеплев П.А. Болезнь Пейрони. Дис. ... канд. мед. наук. М., 1986. 286 с.

Schwarzer U., Sommer F., Klotz T. et al. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001. Vol. 88. P. 727–730.

Lindsay M.B., Schain D.M., Grambsch P. et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991. Vol. 146, No 4. P. 1007–1009.

Dibenedetti D.B., Nguyen D., Zografos L. et al. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011. P. 10–13.

Shiraishi K., Shimabukuro T., Matsuyama H. The prevalence of Peyronie’s disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks. J. Sex. Med. 2012. No 9. P. 2716–2723.

La Pera G., Pescatori E.S., Calabrese M. et al. SIMONA Study Group Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50–69 years. Eur. Urol. 2001. Vol. 40, No 5. P. 525–530.

Mulhall J.P., Creech S.D., Boorjian S.A. et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004. Vol. 171, No 6 (pt. 1). P. 2350–2353.

Gholami S.S., Gonzalez-Cadavid N.F., Lin C.S., Rajfer J., Lue T.F. Peyronie’s disease: a review. J Urol. 2003. No 169. P. 1234–1241.

Bjekic M.D., Vlajinac H.D., Sipetic S.B., Marinkovic J.M. Risk factors for Peyronie’s disease: a case-control study. BJU Int. 2006. No 97. P. 570–574.

Kendirci M., Trost L., Sikka S.C., Hellstrom W.J.G. Diabetes mellitus is associated with severe Peyronie’s disease. BJU Int. 2007. No 99. P. 383–386.

Rhoden E.L., Riedner C.E., Fuchs S.C. et al. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie’s disease. J. Sex. Med. 2010. Vol. 7, No 4 (pt 1). P. 1529–1537.

Nugteren H.M., Nijman J.M., de Jong I.J., van Driel M.F. The association between Peyronie’s and Dupuytren’s disease. Int. J. Impot. Res. 2011. Vol. 23, No 4. P. 142–145.

Carrieri M.P., Serraino D., Palmiotto F. et al. A case-control study on risk factors for Peyronie’s disease. J. Clin. Epidemiol. 1998. Vol. 51, No 6. P. 511–515.

Devine C.J. Jr.,Somers K.D., Jordan S.G. et al. Proposal: trauma as the cause of the Peyronie’s lesion. J. Urol. 1997. No 157. P. 285–290.

Nehra A., Alterowitz R., Culkin D.J. et al. Peyronie’s disease: AUA guideline. J. Urol. 2015. No 194. P. 745–753.

Somers K.D., Dawson D.M. Fibrin deposition in Peyronie’s disease plaque. J. Urol. 1997. Vol. 157, No 1. P. 311–315.

El-Sakka A.I., Hassoba H.M., Pillarisetty R.J. rt al. Peyronie’s disease is associated with an increase in trans-forming growth factor-beta protein expression. Urol. 1997. No 158. P. 1391–1394.

El-Sakka A.I., Hassan M.U., Nunes L. et al. Histological and ultrastructural alterations in an ani-mal model of Peyronie’s disease. Br. J. Urol. 1998. No 81. P. 445–452.

Bivalacqua T.J., Diner E.K., Novak T.E. et al. A rat model of Peyronie’s disease asso-ciated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J. Urol. 2000. No 163. P. 1992–1998.

Francisco G., Ling D.Y., Eric C. et al. A Novel rat model for Peyronie’s disease that dem-onstrates durability and functional detriments. CUA J. 2012. No 6. P. 51.

Iacono F., Barra S. et al. Microstructural disorders of tunica albuginea in patients affected by Peyronie’s disease with or without erection dysfunction. J. Urol. (Baltimore). 1993 Vol. 150, No 6. P. 1806–1809.

Горпинченко И.И., Гурженко Ю.Н. Классификация болезни Пейрони. Приложение к журналу «Андрология и генитальная хирургия». 2002. № 3.

Smith B.H. Peyronie’s disease. J. Urol. (Baltimore). 1966. Vol. 45, No 6. P.670–677.

ЕАУ Guidelines. 2019.

Hatzichristodoulou G. Conservative therapy of Peyronie’s disease. Urologe A. 2015. Vol. 54, No 5. P. 641–647.

Paulis G.2, Paulis A., Romano G. et al. Rationale of combination therapy with antioxidants in medical management of Peyronie’s disease: results of clinical application. Res. Rep. Urol. 2017. Vol. 20. P. 129–139.

Hesong J., Qingqiang G., Xiaoyan C. et al. Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells. Exp. Ther. Med. 2017. Vol. 14, No 5. P. 5149–5156.

Scardino P., Scott W. Ann N. Y. The use of tocopherols in the treatment of Peyronie’s disease. Acad. Sci. 1949. No 52. P. 390.

Tesley G.H. Peyronie’s disease a new approach. J.Urol. 1954. Vol. 71, No 5. P. 611–614.

Bodner H. et al. Peyronie’s disease: cortisone-hyaluronidase-hydrocortisone therapy. J.Urol. 1954. Vol. 72, No 3. P. 400–403.

Gelbard M.K., Walsh R., Kaufman J.J. Collagenase for Peyronie’s disease experimental studies. Urol. Res. 1982. Vol. 10, No 3. P. 135–140.

Gustafson H., Johansson В., Edsmyr F. Peyronie’s disease: experience of local treatment with Orgotein. Eur. Urol. 1981. Vol. 7, No 6. P. 346–348.

Verges J., Chateu A. Nouveau traitment della maladie La Peyronie: la superoxyde desmutase par ionisiations. Comparison avec une serie ancienne cla-sique. Ann. Urol. 1987. P. 143–144.

Duncan M., Berman В., Nseyo U. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasta by interferons-alpha.-beta and -gamma. Scand. J. Urol. Nephrol. 1991. No 25. P. 89–94.

Wegner H., Andresen R. , Knispel H., Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie’s disease. Eur. Urol. 1997. Vol. 32, No 2. P. 190–193.

Brake M., Loertzer H., Horsch R., Keller H. Treatment of Peyronie’s disease with local interferon-alpha 2b. BJU Int. 2001. Vol. 87, No 7. P. 654–657.

Levine L.A., Merrick P.F., Lee R.C. Intralesional verapamil injection for the treatment of Peyronie’s disease. J. Urol. 1994. Vol 151, No 6. P. 152–154.

Lue T.F., Jardin A., Wagner G., Khoury S., Giuliano F., Padma-Nathan H., Rosen R. Peyronie’s Disease. Erectile Disfunction. Paris, 1999. P. 437–475.

Щеплев П.А. Болезнь Пейрони. 2012.

Endo Pharmaceuticals Inc. XiaflexЗ$ (Collagenase Clostridium histolyticum) [prescribing information]. Malvern (PA): Endo Pharmaceuticals Inc, 2016. P. 1–42.

Mandl I., Maclennan J.D., Howes E.L., DeBellis R.H., Sohler A. Isolation and characterization of proteinase and collagenase from Cl. Histolyticum. J. Clin. Invest. 1953. No 32. P. 1323–1329.

Gelbard M.K., Walsh R., Kaufman J.J. Collagenase for Peyronie’s disease experimental studies. Urol. Res. 1982. No 10. P. 135–140.

Levine L.A., Schmid T.M., Emeigh Hart S.G. et al. Collagenase clostridium histolyticum degrades type I and III Collagen while sparing Type IV collagen in vitro in Peyronie’s plaque explants. J. Urol. 2014. No 191. P. 672–673.

Jordan G.H. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: A prospective, single center, non placebo controlled study. J. Sex. Med. 2008. Vol. 5, No 1. P. 180–187.

Levine L.A., Cuzin B., Mark S. et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie’s disease: A phase 3 open label study. J. Sex. Med. 2015. Vol. 12, No 1. P. 248–258.

Gelbard M. et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J. Urol. 2013. Vol. 190, No 1. P. 199–207.

Yafi F.A., Anaissie J., Zurawin J. et al. Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie’s Disease. J. Sex. Med. 2016. No 13. P. 684–689.

Yang K.K., Bennett N. Peyronie’s Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms. Urology. 2016. No 94. P. 143–147.

Nesbit R.M. Congenital curvature of the phallus: report of three cases with description of corrective operation. J. Urol. 1965. No 93. P. 230–232.

Ralph DJ, al-Akraa M, Pryor JP. The Nesbit operation for Peyronie’s disease: 16-year experience. J. Urol. 1995. No 54. P. 1362–1363.

Savoca G., Scieri F., Pietropaolo F. et al. Straightening corpo-roplasty for Peyronie’s disease: A review of 218 patients withmedian follow-up of 89 months. Eur. Urol. 2004. No 46. P. 610–614.

Bokarica P., Parazajder J., Mazuran B. et al. Surgical treatmentof Peyronie’s disease based on penile length and degree ofcurvature. Int. J. Impot. Res. 2005. No 17. P. 170–174.

Licht M.R., Lewis R.W. Modified Nesbit procedure for thetreatment of Peyronie’s disease: A comparative outcomeanalysis. J. Urol. 1997. No 158. P. 460–463.

Horstmann M., Kwol M., Amend B. et al. A self-reported long-term follow-up of patients operated with either shorteningtechniques or a TachoSil grafting procedure. Asian J. Androl. 2011. No 13. P. 326–331.

Rolle L., Tamagnone A., Timpano M. et al. The Nesbit operationfor penile curvature: An easy and effective technical modifi-cation. J. Urol. 2005. No 173. P. 171–173.

Yachia D. Modified corporoplasty for the treatment of penilecurvature. J. Urol. 1990. No 143. P. 80–82.

Lemberger R.J., Bishop M.C., Bates C.P. Nesbit’s Operation for Peyronie’s Disease. British Journal of Urology. 1984. Vol. 56. P. 721–723.

Daitch J.A., Angermeier K.W., Montague D.K. Modified corpo-roplasty for penile curvature: Long-term results and patientsatisfaction. J. Urol. 1999. Vol. 162. P. 2006–2009.

Rehman J., Benet A., Minsky L.S. et al. Results of surgicaltreatment for abnormal penile curvature: Peyronie’s diseaseand congenital deviation by modified Nesbit plication (tunicalshaving and plication). J. Urol. 1997. No 157. P. 1288–1291.

Lopes I., Tomada N., Vendeira P. Penile corporoplasty withYachia’s technique for Peyronie’s disease: Single centerexperience with 117 patients. Urol. Ann. 2013. No 5. P. 167–171.

Щеплев П. А. Принципы оперативного лечения болезни Пейрони. Урология и нефрология. 1983. № 5. C. 43–50.

Essed E., Schroeder F.H. New surgical treatment for Peyronie’sdisease. Urology. 1985. No 25. P. 582–587.

Geertsen U.A., Brok K.E., Andersen B. et al. Peyronie’s curvature treated by plication of the penile fasciae. Essed E, Schroeder FH. BJU. 1996. No 77. P. 733–735.

Gholami S.S., Lue T.F. Correction of penile curvature using the16-dot plication technique: A review of 132 patients. J. Urol. 2002. No 167. P. 2066–2069.

Iacono F., Prezioso D., Ruffo A. et al. Tunical plication in themanagement of penile curvature due La Peyronie’s disease.Our experience on 47 cases. BMC Surg. 2012. Vol. 12. P. 25.

Cantoro U., Polito M., Catanzariti F. et al. Penile plication forPeyronie’s disease: Our results with mean follow-up of 103months on 89 patients. Int. J. Impot. Res. 2014. No 26. P. 156–159.

Lowsley O.S., Boyce W.H. Further experiences with an operation to cure Peyronie’s disease. The Journal of Urology. Vol. 63, No 5. P. 888–902.

Kadioglu A., Sanli O., Akman T. et al. Graft materials in Peyronie’s disease surgery: a comprehensive review. J. Sex. Med. 2007. No 4. P. 581–595.

Professionals S-O. Penile Curvature [Internet]. Uroweb, 2015.

Das S. Peyronie’s disease: excision and autografting with tunicavaginalis. J. Urol. 1980. No 124. P. 818–819.

Das S., Maggio A.J. Tunica vaginalis autografting for Peyronie’s disease: an experimental study. Invest. Urol. 1979. Vol. 17, No 3. P. 186–187.

Amin M., Broghamer W.L. Jr., Harty J.I., Long R. Jr. Autogenous tunica vaginalis graft for Peyronie’s disease: an experimental study and its clinical application. J. Urol. 1980. Vol. 124, No 6. P. 815–817.

Hafez A.T., Smith C.R., McLorie G.A., El-Ghoneimi A., Herz D.B., Bдgli D.J., Khoury A.E. Tunica vaginalis for correcting penile chordee in a rabbit model: is there a difference in flap versus graft? J. Urol. 2001. Vol. 166, No 4. P. 1429–1432.

O’Donnell P.D. Results of surgical management of Peyronie’s disease. J. Urol. 1992. Vol. 148, No 4. P. 1184–1187.

Yuanyuan M., Ning S., Yang W. et al. Testicular tunica vaginalis patch grafting for the treatment ofPeyronie’s disease. Cell. Biochem. Biophys. 2015. No 71. P. 1117–1121.

Kalsi J.S., Christopher N., Ralph D.J., Minhas S. Plaque incision and fascia lata grafting in the surgical management of Peyronie’s disease. BJU Int. 2006. Vol. 98, No 1. P. 110–114.

Gelbard M.K., Hayden B. Expanding contractures of the tunica albuginea due to Peyronie’s disease with temporalis fascia free grafts. J. Urol. 1991. Vol. 145, No 4. P. 772–776.

Kargi E., Ye_illi C., Ho_nuter M., Akduman B. et al. Relaxation incision and fascia lata grafting in the surgical correction of penile curvature in Peyronie’s disease. Plast. Reconstr. Surg. 2004. Vol. 113, No 1. P. 254–259.

Helal M.A., Lockhart J.L., Sanford E. et al. Tunica vaginalis flap for the management of disabling Peyronie’s disease: surgical technique, results, and complications. Urology. 1995. Vol. 46, No 3. P. 390–392.

O’Donnell PD. Results of surgical management of Peyronie’s disease. J. Urol. 1992. Vol.148, No 4. P. 1184–1187.

Yuanyuan M., Ning S., Yang W. et al. Testicular tunica vaginalis patch grafting for the treatment of Peyronie’s disease. Cell. Biochem. Biophys. 2015. Vol. 71, No 2. P. 1117–1121.

Liu B., Li Q., Cheng G. et al. Surgical treatment of Peyronie’s disease with autologous tunica vaginalis of testis. BMC Uro. 2016. Vol. 16, No 1. P. 34–39.

Downloads

Published

2019-09-21

Issue

Vol. 23 No. 3 (2019)

Section

Andrology

License

Стаття повинна мати візу керівника та офіційне направлення від установи, з якої виходить стаття (з круглою печаткою), і вказівкою, чи є стаття дисертаційною, а також у довільній формі на окремому аркуші - відомості про авторів (прізвище, ім’я, по батькові, посада, вчений ступінь, місце роботи, адреса, контактні телефони, E-mail).

Стаття повина бути підписана всіма авторами, які укладають з редакцією договір пропередачу авторських прав (заповнюється на кожного автора окремо з оригінальним підписом). За таких умов редакція має право на її публікацію та розміщення на сайті видавництва.